---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032076"
form_type: "8-K"
ticker: "CDLX"
cik: "0001666071"
company_name: "Cardlytics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:27.900448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardlytics Q1 revenue $34.3M (-39% YoY); net loss narrows to $4.5M; adj EBITDA positive $0.2M

## Summary
- Revenue $34.3M, down 39% YoY from $56.4M; net loss $(4.5)M ($0.08/share) vs $(13.3)M ($0.26) in Q1 2025.
- Adjusted EBITDA $0.2M vs $(4.1)M year ago; first positive quarter; adjusted contribution $19.7M (-28% YoY).
- Completed divestiture of Bridg on March 24, 2026 and subsequently liquidated PAR shares to bolster balance sheet.
- Q2 2026 guidance: revenue $35-40M, billings $61-67M, adjusted EBITDA ($2.7M)-$1.3M.
- Monthly qualified users 197M (-8% YoY); adjusted contribution per user $0.10 vs $0.13.

## SEC filing metadata
- accession: 0001628280-26-032076
- form_type: 8-K
- ticker: CDLX
- cik: 0001666071
- company_name: Cardlytics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1666071/000162828026032076/0001628280-26-032076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1666071/000162828026032076/cdlx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032076
- JSON: https://secwatch.observer/filing/0001628280-26-032076.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032076.txt

## Source-grounded claims
- claim_id: 4342efa7e2c8d95da3cb003f09f7207e43d6695f
  claim: Cardlytics, Inc. reported Q1 2026 results: revenue $34.3 million, net income $(4.5) million, EPS $(0.08) per diluted share.
  evidence_excerpt: Revenue was $34.3 million, a decrease of 39% year-over-year compared to $56.4 million in the first quarter of 2025. • Billings, a non-GAAP metric, was $58.1 million, a decrease of 37% year-over-year compared to $92.1 million in the first quarter of 2025. • Adjusted Contribution, a non-GAAP metric, was $19.7 million, a decrease of 28% year-over-year compared to $27.3 million in the first quarter of 2025. • Net Loss was $(4.5) million, or $(0.08) per diluted share, based on 54.9 million fully diluted weighted-average common shares, compared to a Net Loss of $(13.3) million, or $(0.26) per diluted share, based on 51.9 million fully diluted weighted-average common shares in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1666071/000162828026032076/0001628280-26-032076-index.htm
- claim_id: 6137887e69fa46fc5732b84d4a7dad4428a54977
  claim: Cardlytics, Inc. reported Q2 2026 results: revenue $35.0 - $40.0 million. Guidance initiated.
  evidence_excerpt: Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates): Q2 2026 Guidance YoY Change Billings (1) $61.0 - $67.0 (38%) - (32%) Revenue $35.0 - $40.0 (40%) - (31%) Adjusted Contribution (2) $20.0 - $23.0 (36%) - (27%) Adjusted EBITDA (2) ($2.7) - $1.3 ($5.7) - ($1.7)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1666071/000162828026032076/0001628280-26-032076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.